CA2400950A1 - Orally administered controlled delivery system for once daily administration of ciprofloxacin - Google Patents

Orally administered controlled delivery system for once daily administration of ciprofloxacin Download PDF

Info

Publication number
CA2400950A1
CA2400950A1 CA002400950A CA2400950A CA2400950A1 CA 2400950 A1 CA2400950 A1 CA 2400950A1 CA 002400950 A CA002400950 A CA 002400950A CA 2400950 A CA2400950 A CA 2400950A CA 2400950 A1 CA2400950 A1 CA 2400950A1
Authority
CA
Canada
Prior art keywords
formulation
ciprofloxacin
agent
xanthan gum
sodium alginate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400950A
Other languages
English (en)
French (fr)
Inventor
Naresh Talwar
John N. Staniforth
Ashok Rampal
Gour Mukherji
N. Badri Vishwanathan
Brij Khera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400950A1 publication Critical patent/CA2400950A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002400950A 2000-03-03 2001-02-28 Orally administered controlled delivery system for once daily administration of ciprofloxacin Abandoned CA2400950A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51788700A 2000-03-03 2000-03-03
US09/517,887 2000-03-03
PCT/IB2001/000279 WO2001064183A1 (en) 2000-03-03 2001-02-28 Orally administered controlled delivery system for once daily administration of ciprofloxacin

Publications (1)

Publication Number Publication Date
CA2400950A1 true CA2400950A1 (en) 2001-09-07

Family

ID=24061635

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400950A Abandoned CA2400950A1 (en) 2000-03-03 2001-02-28 Orally administered controlled delivery system for once daily administration of ciprofloxacin

Country Status (31)

Country Link
EP (1) EP1263409A1 (et)
JP (1) JP2003525229A (et)
KR (1) KR20030009374A (et)
CN (1) CN1420763A (et)
AP (2) AP1485A (et)
AR (1) AR032614A1 (et)
AU (1) AU3589701A (et)
BG (1) BG107055A (et)
BR (1) BR0108958A (et)
CA (1) CA2400950A1 (et)
CZ (1) CZ20022883A3 (et)
DO (1) DOP2001000130A (et)
EA (1) EA200200914A1 (et)
EC (1) ECSP013952A (et)
EE (1) EE200200497A (et)
GT (1) GT200100033A (et)
HN (1) HN2001000038A (et)
HR (1) HRP20020715A2 (et)
HU (1) HUP0204417A3 (et)
IL (1) IL151553A0 (et)
IS (1) IS6532A (et)
MX (1) MXPA02008568A (et)
NO (1) NO20024108L (et)
NZ (1) NZ520927A (et)
OA (1) OA12381A (et)
PE (1) PE20011113A1 (et)
PL (1) PL365071A1 (et)
SK (1) SK12542002A3 (et)
WO (1) WO2001064183A1 (et)
YU (1) YU66202A (et)
ZA (1) ZA200206764B (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10351448A1 (de) 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
EP1880722B1 (en) * 2006-07-19 2010-03-17 Tabuk Pharmaceutical Manufacturing Co. Pharmaceutical compositions of ciprofloxacin
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
EP3419669A4 (en) * 2016-02-23 2019-10-30 Matripharm International Inc. DOUBLE-SPEED RELEASE COMPOSITION WITH HIGH MEDICAL DRUG CHARGE
AU2017236977B2 (en) 2016-03-24 2022-05-26 Immunomolecular Therapeutics, Inc. Methods of treating autoimmune disease
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN109806237A (zh) * 2019-03-13 2019-05-28 悦康药业集团上海制药有限公司 一种乳酸环丙沙星泡腾片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE19839057A1 (de) * 1998-08-28 2000-03-02 Koch Berthold Spülluft-Regler für eine Trockenvorrichtung für Druckluft
EP1281397A1 (en) * 1998-09-14 2003-02-05 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control

Also Published As

Publication number Publication date
AR032614A1 (es) 2003-11-19
HN2001000038A (es) 2005-03-23
ECSP013952A (es) 2002-04-23
EA200200914A1 (ru) 2003-02-27
JP2003525229A (ja) 2003-08-26
IS6532A (is) 2002-08-28
NZ520927A (en) 2003-06-30
HRP20020715A2 (en) 2004-12-31
EP1263409A1 (en) 2002-12-11
CN1420763A (zh) 2003-05-28
IL151553A0 (en) 2003-04-10
DOP2001000130A (es) 2004-03-31
GT200100033A (es) 2001-10-25
HUP0204417A2 (en) 2003-05-28
EE200200497A (et) 2004-02-16
AU3589701A (en) 2001-09-12
PL365071A1 (en) 2004-12-27
WO2001064183A1 (en) 2001-09-07
KR20030009374A (ko) 2003-01-29
OA12381A (en) 2004-09-06
AP1485A (en) 2005-10-31
MXPA02008568A (es) 2003-02-24
NO20024108L (no) 2002-10-25
BR0108958A (pt) 2003-09-30
YU66202A (sh) 2005-09-19
PE20011113A1 (es) 2001-10-14
BG107055A (bg) 2003-06-30
AP2002002627A0 (en) 2002-09-30
AP2001002084A0 (en) 2001-03-31
ZA200206764B (en) 2003-03-04
SK12542002A3 (sk) 2003-05-02
HUP0204417A3 (en) 2005-03-29
CZ20022883A3 (cs) 2003-04-16
NO20024108D0 (no) 2002-08-28

Similar Documents

Publication Publication Date Title
US6261601B1 (en) Orally administered controlled drug delivery system providing temporal and spatial control
EP1107741B1 (en) Orally administered controlled drug delivery system providing temporal and spatial control
US6899896B2 (en) Hydrogel-driven layered drug dosage form
US20070196396A1 (en) Controlled release pharmaceutical compositions with improved bioavailability
JPH07558B2 (ja) モピダモール製剤
US20020081332A1 (en) Controlled release formulation of erythromycin or a derivative thereof
JP2005508901A (ja) 活性成分を徐放する剤形
CA2400950A1 (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin
AU2006201553A1 (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
WO2008050188A2 (en) Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
GB2334212A (en) Modified release matrix formulation for cefaclor and cephalexin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued